Thrombus - 2010


Preventing VTE – an education programme for ward nurses
Teresa Tripp, Penney Clarke and Patsy Stevens
pp 1-5
One important part of the remit of the thromboprophylaxis nurse in the Oxford Radcliffe Hospitals NHS Trust is to address the educational needs of all healthcare professionals in relation to the prevention of venous thromboembolism (VTE). In this article, we share our experience of setting up a mandatory education programme aimed at ward nurses.
Comment: Patient safety and the use of low molecular weight heparins
Peter Rose
pp 2-2
Yet another Rapid Response Report from the National Patient Safety Agency (NPSA) has been issued, this time aimed at all healthcare sectors and specialities involved in the prescribing, administering, monitoring and dispensing of low molecular weight heparins (LMWHs). All organisations within the NHS are required to have fulfilled the recommendations by 28 January 2011.
Hughes syndrome – the story so far
Graham RV Hughes
pp 6-9
Graham RV Hughes is a leading light within the field of lupus. He is credited with the discovery of the blood clotting disease now known as Hughes syndrome. In the following extract from his forthcoming book, Tales of a flying doctor and the story behind Hughes syndrome, he explains how the condition came to be discovered.
Patient perceptions of compliance with National Patient Safety Agency Alert 18
Nina Grant, David Gerrett and Bruce Warner
pp 10-12
With the emerging availability of alternative therapies for stroke prevention such as dabigatran, the use of warfarin is likely to decrease in the coming years. However, warfarin is both commonly prescribed and associated with avoidable patient harm, and as such, patient safety guidance for anticoagulant medication is still relevant.
Ensuring good practice in a self-testing LMWH patient
Joan Clifford
pp 14-15
Heidi came from Germany to the UK to attend school at the age of 18. She had had an aortic valve replacement (AVR) at the age of four and had been managing her own anticoagulant treatment, with assistance from her mother, for many years.

Thrombus is funded by an unrestricted educational grant from Bayer HealthCare, with no editorial input into the contents of this journal.

Thrombus was previously supported by Boehringer Ingelheim from 2009 to 2013, by sanofi-aventis from 2007 to 2008 and by Leo Pharma from 1998 to 2006.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the sponsor, publisher, Editor or Editorial Board. Accordingly the sponsor, publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title Thrombus is the property of Hayward Group Ltd and, together with the content, is bound by copyright. Copyright © 2017 Hayward Group Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to: admin@hayward.co.uk

ISSN 1369-8117 (Print)  ISSN 2045-7855 (Online)